Novo Nordisk's Wegovy cuts BMI 13.5% in children aged 6 to under 12 in Phase 3 trial
NVO•Novo Nordisk said Wegovy reduced BMI by 13.5% in children aged 6 to under 12 in the Phase 3 STEP Young trial. The results were presented at ObesityWeek 2026 and published on November 16, 2026.




